Shares of Sana Biotechnology, Inc. (SANA) plummeted 11.84% on Friday, as traders took profits following the stock's massive rally over the past week on upbeat clinical study results.
SANA's stock skyrocketed 151.5% in the past week after the company announced positive initial data from a first-in-human study of its experimental type 1 diabetes cell therapy, UP421. In the study, UP421 was transplanted into a patient without the need for immunosuppression, thanks to Sana's proprietary hypoimmune (HIP) technology.
The results showed survival and functionality of the transplanted pancreatic beta cells, demonstrated by the presence of C-peptide, a biomarker indicating insulin production. Crucially, no safety concerns were identified, and the HIP-modified cells evaded immune responses, eliminating the need for chronic immunosuppression.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。